echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China's pharmaceutical innovation city map , Chengdu: innovation dragon door array.

    China's pharmaceutical innovation city map , Chengdu: innovation dragon door array.

    • Last Update: 2020-07-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Leisure and slow-paced lifestyles are different from the competitiveness of other cities in Chengdu, but can it be a productive force? As early as 2000, "New Weekly" boldly made a city cover topic, breaking the traditional GDP hero of the city evaluation, emphasizing the unique model of urban development, Chengdu as the north to guangzhou first-tier cities after the "leader", and sealed as China's "fourth city."but today, this urban positioning has not made Chengdu truly economically become China's "fourth city", the latest China's urban GDP ranking in 2019 Chengdu ranked seventh, did not enter the "North to Guangshen" first-tier city four, ranked after Chongqing, Suzhoueconomy, Chengdu's industrial positioning is also relatively vague, although with the tianfu New Area's support for the Internet innovation industry, Chengdu in the Internet information industry is growing rapidlyHowever, the Internet industry is relatively "light assets" difficult to build competitive barriers, and the first city Hangzhou, Shenzhen and other competitive advantages are too obviousTraditional manufacturing industries, such as automobiles and energy, are facing obvious challenges in the face of economic transformationin this context, Chengdu will be policy and resources of the baton to the biopharmaceutical innovation industryIn 2018, Aer Jian will land the China Innovation Center in Chengdu, and Chengdu has also set the goal of building a "medical beauty capital"In 2019, the Chengdu Municipal Government issued policies to promote the high-quality development of the biopharmaceutical industry, and on the basis of the 2016 edition, it has strengthened its efforts to encourage pharmaceutical innovation, especially by refining policies to attract pharmaceutical talents and provide high-quality servicesis more important than policy for the development of pharmaceutical innovation industry, the industrial base and peoplePharmaceutical innovation has always been the "pearl in the crown", there is no huge pharmaceutical industry base as a support, there is no benign medical institutionecosystem and rich clinical trial resources as support, pharmaceutical innovation can only be "on paper."the return of scientists and local scientific research personnel is to promote the pharmaceutical innovation and research and development of the real realization of the protagonistAnd Chengdu is using its own way and rhythm, to open up a new ecological medicine innovation?"slow" out of the opportunity
    leisure and slow-paced lifestyle, can become a city's competitive and productive source? The previous answer may have been no, but the answer may yet be to be determinedwith the eastern first-tier cities housing pressure, life pressure is increasing, "escape from the north to Guangzhou" has become a hot topic of discussionAccording to JD.com, the proportion of first-tier cities in Beijing, Shanghai, Guangzhou and Shenzhen has reached 1.13%, 0.95%, 1.05% and 2.56% in 2018Along with the "escape from the north to the wide" together with the heat and the "new line" of the rise of the city THE DIRECT EMPLOYMENT RESEARCH INSTITUTE OF THE
    , IN 2019, THE NET OUTFLOW RATE OF CROSS-CITY EMPLOYMENT IN THE FIRST-TIER CITIES OF BEIJING AND SHENZHEN WAS 0.61%, ACCORDINGLY, HANGZHOU, WUHAN AND CHENGDU BECAME THE FIRST THREE CITIES PREFERRED BY JOB SEEKERS AFTER LEAVING THE FIRST-TIER CITIES And after fleeing the first-tier cities of Guangshen in the north, the reason why medical talents can choose Chengdu, is closely related to Chengdu's solid pharmaceutical industry base, rich university resources and friendly talent introduction policy Official data from the show that in 2019, Chengdu's biopharmaceutical industry enterprises above the city's size achieved 59.6 billion yuan in main business revenue, up 21.6% year-on-year Cheng has trained Colum Pharmaceuticals, Kanghong Pharmaceuticals, Theo Group, Good DoctorS Pharmaceuticals and many other large-scale local pharmaceutical companies in addition to cultivating large local pharmaceutical companies, Chengdu has attracted generous investment sized by large foreign pharmaceutical companies by virtue of its location, cost and talent advantages Foreign pharmaceutical companies such as Aljian, Sanofi, Medtroni and GE have invested in and built an innovation center in Chengdu, and AstraZeneca will also land in the Chengdu High-tech Zone at the same time, Chengdu brings together Sichuan University, Chengdu University of Traditional Chinese Medicine and many other universities, has a wealth of scientific research and new medical personnel resources, which can provide better academic and talent interaction for the influx of medical talents on the basis of its own industrial advantages, Chengdu timely launched to attract high-end expert stoic talent "floating" plan, which for chengdu pharmaceutical industry innovation talent super-construction provides a complement In 2011, Chengdu launched the "Floating Plan", "Floating Plan" aims to introduce innovative projects and talents from the outside, for all kinds of selected experts to provide a range of 600,000 to 3 million grants, for the top innovation and entrepreneurship team each to give 5 million yuan of funding by the end of 2019, the cumulative cashing of talent funding funds of the "Yulu Plan" exceeds 800 million yuan Under the attraction of rich funding, Chengdu cumulative selection of the introduction of "Floating Plan" special experts 799, the top innovation and entrepreneurial team 78, including pharmaceutical innovation talent, such as the southwest's first landing in the company's first pharmaceutical innovation enterprise Chengdu pilot founder Li Jin and what are the opportunities and strengths of medical innovation in Chengdu? The medicine "floating" undoubtedly has the most say Why do "drift" come? lijin, , is not a Chengdu native, and the first to tie up with Chengdu was because he came to Chengdu to attend a conference At that time, Chengdu, especially the high-tech areas of people and things have left a deep impression on him Li Jin felt that compared to the "north bounds", the cost of enterprise development in Chengdu is lower, the development environment is also good "Chengdu has some big pharmaceutical companies like Teo Chengdu also has Huaxi Hospital, do medical development, there is a good hospital is always good "Li Jin thinks the foundation of the drug industry in Chengdu is good attracted by Chengdu's unique location advantages, Li Jin finally chose to create Chengdu Pilot in Chengdu High-tech Zone Although the international large pharmaceutical companies have their own compound library and pilot compound screening platform, but the use of "DNA coding small molecular compound synthesis and screening technology" for pharmaceutical enterprises to provide specialized services to the world only three enterprises, Chengdu pilot is one of them, but also the only one in the country with the cutting-edge "DNA coding small molecular compound synthesis and screening technology", Chengdu Pilot became the first in the southwest region to successfully land on the Shanghai Stock Exchange's biopharmaceutical innovation enterprises not only The founder of Chengdu Pilot Li Jin, more other "sea return" high-end pharmaceutical talent also choose Chengdu landing start-up Chen Yuanwei, founder and president of Haitron Pharmaceuticals, recalled that he first returned to Chengdu from overseas in 2008, when Chengdu is vigorously developing biomedicine, industry innovation and entrepreneurship ranked in the forefront of the country, in Chengdu at all levels of government and related units of the promotion and guidance, in the talent support, industry support, capital support and other aspects of help, see Chengdu vigorously develop bio-medicine determination and courage, and therefore choose Chengdu as the starting point of entrepreneurship July 26, 2019, Haitron Pharmaceuticals has completed a US$40 million round B financing for the treatment of the new drug HC-1119 Global Multicenter III Clinical, Gout Product siphone product I/II clinical and other product research "sea return", Chengdu has also attracted the eastern pharmaceutical innovation talent on the ground to start a business In 2016, Chen Bo, co-founder of Junshi Bio, founded Kangnoa Biopharmaceutical Technology in Chengdu after leaving Junshi Bio, and its co-founder is Wang Changyu, a key research and development scientist for O Pharmaceuticals (commodity name: Opdivo) Chengdu has become the starting point for many pharmaceutical innovation talents New District Innovation Group
    an innovative pharmaceutical enterprise is not called pharmaceutical innovation, a group of innovative pharmaceutical enterprises with their own characteristics together is the real pharmaceutical innovation as early as 1988, Chengdu High-tech Zone has begun to build, and in 1991 was approved by the State Council to become the first national high-tech industrial development zone Chengdu High-tech Zone ranks 6th in the 2018 China National Industrial Park's 100 Thia List of Sustainable Development Competitiveness, released by the Ministry of Science and Technology, while Chengdu High-tech Zone is one of the leading industries in the development of the High-tech Zone of Chengdu, which is the biopharmaceutical industry, and a group of Chengdu's biopharmaceutical innovation enterprises have taken root in Chengdu High-tech Zone Chengdu High-tech Zone not only brings together the Dio Group, Haicisco Pharmaceuticals and other large chemical pharmaceutical enterprises, but also attracts a large number of innovative pharmaceutical enterprises to take root, focusing on bio-3D printing of Blu-ray Inno, focusing on high-tech medical imaging technology Ofai medical, deep-cultivated radioactive drugs Ofi, deep-cultivated innovative drugs Ofano, focusing on the drug and innovative drugs of Haitron Pharmaceuticals have chosen to start a business in Chengdu High-tech Zone and Chengdu High-tech District has hatched an IVD enterprise Mike Bio that successfully landed on the Shenzhen Stock Exchange clearly, Chengdu is not satisfied with relying solely on Chengdu High-tech Zone to provide support for biopharmaceutical innovation In 2014, Chengdu was approved by the State Council to set up a new area of Tianfu, a state-level In particular, it is worth noting that Tianfu New Area hatched the southwest region's first successful landing of the pharmaceutical innovation enterprise Chengdu pilot Chengdu Pilot successfully landed on the Shanghai Stock Exchange on April 16, 2020, the opening price of 40 yuan, up 94.93 percent from the issue price, and the closing price of revenue of 47.08 yuan, up 129.43 percent from the issue price, the first day market value of The Chengdu Pilot listing exceeds 18 billion yuan has launched a more targeted regional construction plan for the pharmaceutical industry after the two "new zones" continued to provide innovative impetus In June 2019, the Chengdu municipal government issued a number of policies to promote high-quality development of Chengdu's biopharmaceutical industry, in addition to raising the incentive standards to support innovation in pharmaceutical research and development, but also put forward the goal of cultivating 20 billion and 100 billion levels of pharmaceutical health enterprises, a number of head enterprises, unicorn enterprises, to build more than 3 unique characteristics, world-class level of 100 billion industrial functional areas large-scale pharmaceutical companies re-innovation in attracting pharmaceutical "floating" talents into the entrepreneurship, Chengdu itself has a strong pharmaceutical industry base, the cultivation of the Group, good doctors pharmaceutical, Collum Pharmaceuticals, Kanghong Pharmaceuticals and many other large-scale pharmaceutical enterprises, and these enterprises are also in the current industrial transformation of the new opportunities for pharmaceutical innovation Kanghong Pharmaceuticals developed a class of innovative drug Compaqip in the field of ophthalmology innovation drugs to open up the market, and pressure foreign ophthalmology innovation drug competition Driven by innovation, Kanghong Pharmaceuticals' performance after landing in the capital market in 2015 has been growing at a high rate for three consecutive years, with operating income of 1.67 billion yuan, 2.07 billion yuan and 2.54 billion yuan from 2014 to 2016, respectively, maintaining a year-on-year increase of more than 20%, and the annual return on net assets of more than 15% Since then, Kanghong Pharmaceuticals has continued to invest in research and development innovation, with the latest annual report showing that Kanghong Pharmaceuticals' research and development investment in 2019 amounted to 788 million yuan, an increase of 125.74 percent over the same period in 2018 in addition to Kanghong Pharmaceuticals, Collum Pharmaceuticals is also a representative of the transformation and innovation of large-scale chemical pharmaceutical enterprises In 2012, Wang Jingyi moved from Qilu Pharmaceuticals to Collon Pharmaceuticals, where he served as president of the Collum PharmaceuticalS Pharmaceutical Research Institute, leading the research and development of Collum Pharmaceuticals As of June 2020, 42 generic products have been approved for production and 12 innovative drug projects have been approved for clinical use after the introduction of scientific talent spawned a significant contribution to innovation, Collum Pharmaceuticals also fulfilled its commitment to innovation incentives On May 29, 2020, Collum Pharmaceuticals announced that it would transfer its 10% stake (i.e 10 million shares and 10 million yuan) each of its subsidiaries, Sichuan Columbotai Bio and Sichuan Collon Pharmaceutical Research Institute, to Wang Jingyi, President and Chief Scientist of Columpharmaceutical Global Research and Development, at a consideration of 1 yuan Chengdu is located in the southwest, the pharmaceutical industry is firmly based, Sichuan Huaxi Hospital in many specialized areas of the best, there are many universities to transport a large number of pharmaceutical talent, while training a lot of large pharmaceutical enterprises, and the enterprise industry and talent policy also attracted innovative pharmaceutical talent into innovation and entrepreneurship, the overall cost of entrepreneurship is also significantly lower than in the east but the gap between Chengdu and the eastern city's economy, talent and so on is still obvious, Chengdu, like San Diego, California, to build a "utopia" of pharmaceutical innovation in the west, there are many challenges and difficulties to overcome.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.